# Pegfilgrastim-gema Compared to Pegfilgrastim-roche for Prevention of Induced Neutropenia in Breast Cancer Patients.

> **NCT03404752** · PHASE3 · UNKNOWN · sponsor: **Gema Biotech S.A.** · enrollment: 120 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Peg-Filgrastim

## Key facts

- **NCT ID:** NCT03404752
- **Lead sponsor:** Gema Biotech S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-08
- **Primary completion:** 2018-06
- **Final completion:** 2018-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2018-01-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03404752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03404752, "Pegfilgrastim-gema Compared to Pegfilgrastim-roche for Prevention of Induced Neutropenia in Breast Cancer Patients.". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT03404752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*